$30 million funding to pursue new autism drug
Cambridge, MA-based Seaside Therapeutics recently announced that it has raised $30 million to pursue mid-stage clinical trial development on new therapies for Fragile X Syndrome and autism.
CEO Randall L. Carpenter explained that the aim of the drug is to not only help symptoms of irritability found in many autistic children, but also to improve other symptoms of social interaction difficulties.
“It may allow individuals to speak, to learn normally,” he explains. “It may enhance their ability to relate to the environment, be more calm and less anxious and potentially more interactive. We’re seeing profound effects in our animal models; how that translates to humans is what we’ll find out in the next year or two.”
Read more: http://www.fiercebiotech.com/story/seaside-gets-30m-pursue-new-autism-drug/2009-09-17#ixzz0T4pnzFRW
